AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
February 20 2018 - 8:00AM
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company
developing treatments for patients suffering from rare and
life-threatening neurological genetic diseases, will report
financial and operating results for the fourth quarter and full
year ended December 31, 2017, as well as recent corporate
highlights, on Tuesday, February 27, 2018, after the close of
U.S.-based financial markets. AveXis management will host a
conference call and live webcast at 4:30 p.m. Eastern Standard
Time.
Analysts and investors can participate in the conference call by
dialing (844) 889-6863 for domestic callers and (661) 378-9762 for
international callers, using the conference ID 1599399. The webcast
can be accessed live on the Events and Presentations page in the
Investors and Media section of the AveXis website, www.AveXis.com.
The webcast will be archived on the company’s website until its
next quarterly earnings call, and will be available for telephonic
replay for 14 days following the call by dialing (855) 859-2056
(Domestic) or (404) 537-3406 (International), conference ID
1599399.
About SMA SMA is a severe neuromuscular disease
characterized by the loss of motor neurons leading to progressive
muscle weakness and paralysis. SMA is caused by a genetic defect in
the SMN1 gene that codes SMN, a protein necessary for survival of
motor neurons. The incidence of SMA is approximately one in 10,000
live births. SMA is the leading genetic cause of infant
mortality.
The most severe form of SMA is Type 1, a lethal genetic disorder
characterized by motor neuron loss and associated muscle
deterioration, which results in mortality or the need for permanent
ventilation support before the age of two for greater than 90
percent of patients. SMA Type 2 typically presents between six and
18 months of age, and those affected will never walk without
support and most will never stand without support. SMA Type 2
results in mortality in more than 30 percent of patients by the age
of 25.
About AVXS-101AveXis’ initial product
candidate, AVXS-101, is its proprietary gene therapy currently in
development for the one-time treatment of SMA Types 1 and 2,
designed to address the monogenic root cause of SMA and prevent
further muscle degeneration by addressing the defective and/or loss
of the primary SMN gene. AVXS-101 also targets motor neurons,
providing rapid onset of effect and crossing the blood brain
barrier to allow effective targeting of both central and systemic
features.
About AveXis, Inc.AveXis is a clinical-stage
gene therapy company developing treatments for patients suffering
from rare and life-threatening neurological genetic diseases. The
company’s initial product candidate, AVXS-101, is its proprietary
gene therapy currently in the pivotal phase of study for the
treatment of SMA Type 1, and in a Phase 1 trial for SMA Type 2. The
company also intends to expand the study of gene therapy into two
additional rare neurological monogenic disorders: Rett syndrome
(RTT) and a genetic form of amyotrophic lateral sclerosis (ALS)
caused by mutations in the superoxide dismutase 1 (SOD1) gene.
For additional information, please visit www.avexis.com.
Media Inquiries:Lauren BarbieroW2O
Group646-564-2156lbarbiero@w2ogroup.com
Investor Inquiries: Jim GoffAveXis,
Inc.650-862-4134jgoff@avexis.com
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jul 2023 to Jul 2024